Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Residual Tumor”

751 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 751 results

Very early researchStudy completedNCT04130152
What this trial is testing

Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

Who this might be right for
Breast Cancer
SOLTI Breast Cancer Research Group 22
Large-scale testing (Phase 3)UnknownNCT01088737
What this trial is testing

Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna

Who this might be right for
Lentigo Maligna
Medical University of Graz 60
Testing effectiveness (Phase 2)Looking for participantsNCT07067268
What this trial is testing

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Who this might be right for
Nasopharyngeal Cancinoma (NPC)
Fudan University 76
Testing effectiveness (Phase 2)Ended earlyNCT01088035
What this trial is testing

Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma

Who this might be right for
Ependymoma
Ann & Robert H Lurie Children's Hospital of Chicago 75
Early research (Phase 1)Ended earlyNCT00041691
What this trial is testing

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer Patients With Limited Residual Disease After Surgery

Who this might be right for
Colorectal Neoplasms
Gilead Sciences 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06570915
What this trial is testing

Daratumumab for T Cell ALL With MRD-positive After Standard Chemotherapy

Who this might be right for
ALL, Adult
Institute of Hematology & Blood Diseases Hospital, China 20
Not applicableLooking for participantsNCT06991868
What this trial is testing

Prospective Cohort Study on Monitoring Recurrence of Urothelial Carcinoma Based on Detection of Urinary Microscopic Residual Disease (MRD)

Who this might be right for
NMIBCMIBCUTUC
Peking University First Hospital 300
Testing effectiveness (Phase 2)Looking for participantsNCT05343013
What this trial is testing

TAS-102 With or Without Celecoxib in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy

Who this might be right for
Colorectal Cancer
M.D. Anderson Cancer Center 25
Not applicableLooking for participantsNCT06744296
What this trial is testing

Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck

Who this might be right for
Squamous Cell Carcinoma of Head and Neck
Massachusetts Eye and Ear Infirmary 75
Not applicableUnknownNCT02872662
What this trial is testing

Individual Molecular MRD Monitoring for MDS Patients After Allo-SCT

Who this might be right for
MDSSCTMRD
Nordic MDS Group 200
Not applicableStudy completedNCT02716103
What this trial is testing

Assessment of Minimal Residual Disease (MRD) After Antineoplastic Treatment in Patients With AL Amyloidosis

Who this might be right for
Amyloidosis
Boston Medical Center 45
Large-scale testing (Phase 3)Study completedNCT01864746
What this trial is testing

Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Who this might be right for
Breast CancerHormonreceptor PositiveHer2-normal+2 more
GBG Forschungs GmbH 1,250
Testing effectiveness (Phase 2)Study completedNCT01575860
What this trial is testing

Maintenance Lenalidomide in Lymphoma

Who this might be right for
Lymphoma
Abramson Cancer Center at Penn Medicine 8
Not applicableActive Not RecruitingNCT04599309
What this trial is testing

Real-time Detection of ctDNA and/or HPV DNA in High-risk Locally-advanced Head and Neck Squamous Cell Carcinoma

Who this might be right for
CancerHead and Neck Squamous Cell CarcinomaHead and Neck Cancer
University Health Network, Toronto 35
Early research (Phase 1)Looking for participantsNCT06138587
What this trial is testing

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

Who this might be right for
Acute Myeloid LeukemiaLeukemiaLeukemia, Myeloid+3 more
Dana-Farber Cancer Institute 15
Not applicableLooking for participantsNCT06443684
What this trial is testing

Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Shanghai Chest Hospital 305
Testing effectiveness (Phase 2)Looking for participantsNCT06992336
What this trial is testing

Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy

Who this might be right for
Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 411
Not applicableActive Not RecruitingNCT02633111
What this trial is testing

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
B-cell Non-Hodgkin LymphomaAggressive
Memorial Sloan Kettering Cancer Center 501
Not applicableStudy completedNCT06000306
What this trial is testing

MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse

Who this might be right for
Measurable Residual Disease
Zhejiang University 192
Testing effectiveness (Phase 2)Study completedNCT02567253
What this trial is testing

Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer

Who this might be right for
Ovarian CancerPrimary Peritoneal Cancer
University Hospital, Ghent 56
Load More Results